950348-60-4
950348-60-4
Chemical Structure
SLC26A3-IN-2
- CAS. Nr.: 950348-60-4
- Formula:C19H13ClN2O2S
- Molecular Weight:368.84
IUPAC Name: 7-((2-chlorophenoxy)methyl)-3-phenyl-5H-thiazolo[3,2-a]pyrimidin-5-one
InChIKey: MXPJASIJFFIVEL-UHFFFAOYSA-N
SMILES: O=C1C=C(N=C2SC=C(N12)C3=CC=CC=C3)COC4=C(C=CC=C4)Cl
Biological Activity: SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SLC26A3-IN-2 | 99.88% | SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tilomisole | Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GNE 6901 | 99.31% | GNE 6901 (compound 40) is a potent GluN2A-selective NMDAR positive allosteric modulator (PAM) with an EC50 of 382 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SCR7 pyrazine (Standard) | SCR7 pyrazine (Standard) is the analytical standard of SCR7 pyrazine (HY-107845). This product is intended for research and analytical applications. SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VA-K-14 hydrochloride | 98.96% | VA-K-14 hydrochloride is a specific thyroid-stimulating hormone receptor (TSHR) antagonist (IC50= 12.3 μM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GABAA receptor agent 7 | GABAA receptor agent 7 (compoud 5c) is a potent GABAA receptor positive modulator. GABAA receptor agent 7 shows anticonvulsant activity in vitro and in vivo with low neurotoxicity. GABAA receptor agent 7 has the potential for the research of epilepsy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sirtuin modulator 2 | 99.22% | Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED50 equal or less than 50 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WT-TTR inhibitor 1 | WT-TTR inhibitor 1 (Compound 21) is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CDK1-IN-7 | CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. CDK1-IN-7 inhibits the proliferation and migration of HCT116 and Lovo cells. CDK1-IN-7 can be used in the study of colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IDO1-IN-31 | IDO1-IN-31 (Compound 17g) is an IDO1 agonist with an IC50 of 77 nM. IDO1-IN-31 can be used for the study of neurological diseases and cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FABP4/5-IN-7 | FABP4/5-IN-7 is a dual FABP4/FABP5 inhibitor, with an IC50 of 0.8 μM and a Kd of 0.01 μM for FABP4, and an IC50 of 1.4 μM for FABP5. FABP4/5-IN-7 inhibits lipolysis in adipocytes. FABP4/5-IN-7 inhibits MCP-1 release in macrophages. FABP4/5-IN-7 improves dyslipidemia in diet-induced obese mice. FABP4/5-IN-7 can be used in studies related to dyslipidemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
